[Predictive Role of EGFR Mutation Status on Postoperative Prognosis in Patients with Resected Lung Adenocarcinomas]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2013 Apr 23

PMID 23601297

Citations 3

Authors

Yu Dong

Ying Li

Hong Peng

Bo Jin

Aimi Huang

Hao Bai

Hui Xiong

Baohui Han

Affiliations

Soon will be listed here.

Abstract

Background: At present the proportion of lung adenocarcinomas in NSCLC is higher than before. Thus, the study on prognosis of lung adenocarcinoma is extremely important. The predictive value of epidermal growth factor receptor (EGFR) mutations for prognosis in patients with resected lung adenocarcinomas has not be reported in China. The aim of this study is to analyze the association between the EGFR mutations and the outcomes of patients with resected lung adenocarcinomas.

Methods: Total of 301 patients with stage Ia-IIIa resected lung adenocarcinomas whose survival had been identified were retrospectively analyzed. Their EGFR mutations were detected by real-time quantitative PCR and DNA sequencing technology together.

Results: The proportion of EGFR mutation was 52.5% (158/301). The 2-year (disease-free survival, DFS) of EGFR-mutant group and wild-type EGFR group was 76.8%, 83.0%; 5-year overall survival (OS) of them was 67.7%, 65.7%. There was no significant difference for two groups (P = 0.252, P = 0.715). Further analysis for subgroups shows that the 2-year DFS, 5-year OS of mutant group and wild-type group in stage I-II was similar. For the patients with stage IIIa, the median DFS, 2-year DFS in mutant group was 12.2 months, 21.1%, lower than the 22.2 months, 42.1% in wild-type group. But there was no significant difference for both groups (P = 0.584, P = 0.295). The median OS, 5-year OS was 34.0 months, 30.8% in mutant group, while 38.7 months, 22.9% in wild-type group. There was no significant difference for both groups (P = 0.907, P = 0.444).

Conclusions: EGFR-mutant group with resected lung adenocarcinomas has a tendency of lower DFS than the wild-type EGFR group only in stage IIIa, but there was no significant difference for both groups. The EGFR mutation status was not associated with disease-free survival or overall survival in resected lung adenocarcinomas.

Citing Articles

Somatic mutations combined with clinical features can predict the postoperative prognosis of stage IIIA lung adenocarcinoma.

Li J, Lin X, Li X, Zhang W, Sun D Ann Transl Med. 2022; 10(4):187.

PMID: 35280419 PMC: 8908182. DOI: 10.21037/atm-22-130.

The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures.

He Q, Xin P, Zhang M, Jiang S, Zhang J, Zhong S Transl Lung Cancer Res. 2019; 8(2):124-134.

PMID: 31106123 PMC: 6504652. DOI: 10.21037/tlcr.2019.03.14.

Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis.

Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y PLoS One. 2014; 9(8):e106053.

PMID: 25162713 PMC: 4146589. DOI: 10.1371/journal.pone.0106053.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Chansky K, Sculier J, Crowley J, Giroux D, Meerbeeck J, Goldstraw P . The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):792-801. DOI: 10.1097/JTO.0b013e3181a7716e. View

Mak R, Doran E, Muzikansky A, Kang J, Neal J, Baldini E . Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011; 16(6):886-95. PMC: 3228219. DOI: 10.1634/theoncologist.2011-0040. View

Lee Y, Park I, Park M, Choi H, Cho B, Chung K . Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2009; 135(12):1647-54. DOI: 10.1007/s00432-009-0611-7. View

Douillard J, Shepherd F, Hirsh V, Mok T, Socinski M, Gervais R . Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2009; 28(5):744-52. DOI: 10.1200/JCO.2009.24.3030. View

Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti F . Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Am J Clin Oncol. 2013; 37(4):343-9. DOI: 10.1097/COC.0b013e31827a7e7a. View

Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun O . Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol. 2012; 7(9):1471-3. DOI: 10.1097/JTO.0b013e3182614a9d. View

Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E . Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 2009; 69(1):110-5. DOI: 10.1016/j.lungcan.2009.09.010. View

Park E, Lee H, Kim Y, Kang C, Kang K, Jeon Y . EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung Cancer. 2008; 64(2):179-86. DOI: 10.1016/j.lungcan.2008.08.003. View

10.

Sasaki H, Shimizu S, Okuda K, Kawano O, Yukiue H, Yano M . Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer. 2008; 64(3):295-300. DOI: 10.1016/j.lungcan.2008.10.005. View

11.

Galleges Ruiz M, Floor K, Steinberg S, Grunberg K, Thunnissen F, Belien J . Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer. 2008; 100(1):145-52. PMC: 2634682. DOI: 10.1038/sj.bjc.6604781. View

12.

Liu H, Wu H, Chang J, Wu Y, Yang H, Chen Y . Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol. 2010; 5(8):1175-84. DOI: 10.1097/JTO.0b013e3181e2f4d6. View

13.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L . Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27(10):1667-74. PMC: 3341799. DOI: 10.1200/JCO.2008.19.1635. View

14.

Chen W, Zeng H, Zheng R, Zhang S, He J . Cancer incidence and mortality in china, 2007. Chin J Cancer Res. 2013; 24(1):1-8. PMC: 3555260. DOI: 10.1007/s11670-012-0001-6. View

15.

Liu Y, Zhu J, Zhang L, Zhang T, Zhang Z, Wang C . [Epithelial growth factor receptor mutation status to the effective of survival in non-small cell lung cancer after surgery]. Zhonghua Wai Ke Za Zhi. 2013; 50(12):1082-6. View

16.

Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T . Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2008; 4(1):22-9. DOI: 10.1097/JTO.0b013e3181914111. View

17.

Li F, Bai H, Li X, Wu M, Yu R, Shi A . [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy]. Zhongguo Fei Ai Za Zhi. 2011; 14(9):715-8. PMC: 5999609. DOI: 10.3779/j.issn.1009-3419.2011.09.03. View

18.

Zhuo M, Wu M, Zhao J, Song S, Bai H, Wang S . Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl). 2012; 124(21):3510-4. View

19.

Koh Y, Jang B, Jeon Y, Kim T, Lee S, Kim D . EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Jpn J Clin Oncol. 2011; 41(4):548-54. DOI: 10.1093/jjco/hyq248. View